JACKSONVILLE, Fla. — A new multicenter study led by Mayo Clinic researchers has established a practical, evidence-based definition for rapidly progressive dementia (RPD), a rare but devastating form ...

Please provide your email address to receive an email when new articles are posted on . The introduction of additional neflamapimod in an open-label extension led to significant clinical improvements.

Neflamapimod, an experimental, oral drug targeting neuroinflammation being developed by CervoMed, led to a significant reduction in a key blood biomarker of neurodegeneration, which correlated with a ...

New data from a phase IIb trial extension study suggested that investigational neflamapimod led to significant improvements on key outcomes in people with dementia with Lewy bodies (DLB). In the ...

Findings showed the change from baseline in CDR-SB score was not significantly improved with semaglutide compared with placebo. Oral semaglutide did not significantly reduce disease progression in ...

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b ...

The diagnosis and severity assessment of Alzheimer’s disease (AD) is a complex procedure that requires clinicians to perform a comprehensive review of multiple factors, including biomarkers, physical ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. New research bolsters evidence that people with early signs of Alzheimer’s can take ...

Please provide your email address to receive an email when new articles are posted on . Earlier initiation of donanemab reduced the risk of disease progression on the Clinical Dementia Rating-Global ...

After adjusting for age, hallucinations and a normal CSF white blood cell count were independently associated with rapidly progressive dementia. Factors such as hallucinations, cortical visual loss, ...